Get real. The FDA will not even let you make that claim as you make reference to Ryoncil. Well not for 12 years anyway. You have to prove that your product is up for the job, comparison to MSB cells will not be allowed. There are literally hundreds of research papers all of which reference MSB research. Not allowed in a BLA . So even if you were to generate your own research you are locked out of the pediatric indication for 7 years. Of course you may ask why the market didn't respond significantly to this announcement, perhaps it was because MSB already had protection through many global patents.
Never mind you still have adults. How you get ahead of MSB is up for debate. Perhaps it would be more aggressive for CYP to put the past behind them , congratulate Mesoblast , terminate your current trial ( which now will be unable to have a control due to the availability of MSCs as a salvage therapy) and more on with other more profitable indications. You have magnificent data on other indications or do you? Prioritise, 5 years late, better late than never.
CYP Price at posting:
18.0¢ Sentiment: Sell Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)